News | Deal AnnouncementLeerink Partners Serves as Lead-Left Bookrunner for Immunovant’s (Nasdaq: IMVT) $450 Million Common Stock FinancingSeptember 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for HilleVax’s (Nasdaq: HLVX) $100 Million Follow-On OfferingSeptember 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Rocket Pharmaceuticals’ (Nasdaq: RCKT) $175 Million Follow-On OfferingSeptember 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Crinetics Pharmaceuticals’ (Nasdaq: CRNX) $350 Million Upsized Follow-On OfferingSeptember 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for AN2 Therapeutics’ (Nasdaq: ANTX) $70 Million Follow-On OfferingSeptember 2023
News | Deal AnnouncementLeerink Partners Serves as a Financial Advisor on Decibel Therapeutics’ Sale to RegeneronAugust 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Turnstone Biologics’ (Nasdaq: TSBX) $80 Million Initial Public OfferingJuly 2023
News | Deal AnnouncementLeerink Partners Serves as Lead Placement Agent for Gossamer Bio’s (Nasdaq: GOSS) $212 Million Private PlacementJuly 2023
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor for Neoleukin Therapeutics’ (Nasdaq: NLTX) Proposed Merger with NeurogeneJuly 2023
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor for Pardes Biosciences’ (Nasdaq: PRDS) Proposed Acquisition by MediPacific, Inc.July 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Caribou Biosciences’ (Nasdaq: CRBU) $125 Million Follow-On OfferingJuly 2023
